NYSE:NUVB Nuvation Bio (NUVB) Stock Forecast, Price & News $1.33 -0.06 (-4.32%) (As of 09/22/2023 ET) Add Compare Share Share Today's Range$1.33▼$1.4550-Day Range$1.27▼$2.1052-Week Range$1.18▼$2.55Volume907,944 shsAverage Volume885,059 shsMarket Capitalization$291.19 millionP/E RatioN/ADividend YieldN/APrice Target$4.38 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Nuvation Bio MarketRank™ ForecastAnalyst RatingModerate Buy2.75 Rating ScoreUpside/Downside228.9% Upside$4.38 Price TargetShort InterestHealthy1.52% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment1.17Based on 4 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($0.40) to ($0.48) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.40 out of 5 starsMedical Sector217th out of 963 stocksPharmaceutical Preparations Industry86th out of 458 stocks 3.4 Analyst's Opinion Consensus RatingNuvation Bio has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 3 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $4.38, Nuvation Bio has a forecasted upside of 228.9% from its current price of $1.33.Amount of Analyst CoverageNuvation Bio has only been the subject of 2 research reports in the past 90 days. Previous Next 4.0 Short Interest Percentage of Shares Shorted1.52% of the float of Nuvation Bio has been sold short.Short Interest Ratio / Days to CoverNuvation Bio has a short interest ratio ("days to cover") of 4.8.Change versus previous monthShort interest in Nuvation Bio has recently decreased by 7.63%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldNuvation Bio does not currently pay a dividend.Dividend GrowthNuvation Bio does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for NUVB. Previous Next 2.9 News and Social Media Coverage News SentimentNuvation Bio has a news sentiment score of 1.17. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.52 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Nuvation Bio this week, compared to 0 articles on an average week.Search InterestOnly 3 people have searched for NUVB on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Nuvation Bio insiders have not sold or bought any company stock.Percentage Held by Insiders36.09% of the stock of Nuvation Bio is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions63.54% of the stock of Nuvation Bio is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Nuvation Bio are expected to decrease in the coming year, from ($0.40) to ($0.48) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Nuvation Bio is -3.24, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Nuvation Bio is -3.24, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioNuvation Bio has a P/B Ratio of 0.44. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Nuvation Bio (NYSE:NUVB) StockNuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-868, a selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation, including oncogenes comprising c-myc; NUV-1156, an AR binder Xtandi that address advanced stage prostate cancers with the potential to move into earlier lines typically treated with surgical prostatectomy; and drug-drug conjugate (DDC) platform that focuses on targeting an inhibitor of poly ADP ribose polymerase (PARP) to anti-cancer warheads of existing drugs, as well as NUV-1176, a PARP inhibitor to address ER+ breast and ovarian cancer. Nuvation Bio Inc. was founded in 2018 and is headquartered in New York, New York.Read More NUVB Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart NUVB Stock News HeadlinesSeptember 23, 2023 | americanbankingnews.comOleg Nodelman Acquires 5,143,000 Shares of Nuvation Bio Inc. (NYSE:NUVB) StockSeptember 22, 2023 | benzinga.comNuvation Bio And 3 Other Stocks Under $4 Insiders Are BuyingSeptember 24, 2023 | Behind the Markets (Ad)BREAKING: The truth about war with ChinaForeign Affairs reports, "China is Now in a Prewar Tempo of Political and Military Preparations." China has one goal: take control of Taiwan, and an invasion could happen any day. I've identified 5 investments I believe are in immediate danger. But you can get out of them now - before it's too late.August 21, 2023 | msn.comHC Wainwright & Co. Reiterates Nuvation Bio Inc - (NUVB) Buy RecommendationAugust 5, 2023 | markets.businessinsider.comRBC Capital Reaffirms Their Buy Rating on Nuvation Bio (NUVB)August 3, 2023 | finance.yahoo.comNuvation Bio Reports Second Quarter 2023 Financial Results and Provides Business UpdateJune 1, 2023 | finance.yahoo.comNuvation Bio Announces Formation of Oncology-Focused Scientific Advisory BoardMay 16, 2023 | finance.yahoo.comNuvation Bio Insider Ups Holding During YearSeptember 24, 2023 | Behind the Markets (Ad)66,000% upside on tiny biotech?The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.May 16, 2023 | finance.yahoo.comNuvation Bio Insider Ups Holding During Year \May 11, 2023 | morningstar.comNuvation Bio Inc Ordinary Shares - Class AMay 6, 2023 | msn.comRBC Capital Maintains Nuvation Bio Inc - (NUVB) Outperform RecommendationMay 5, 2023 | markets.businessinsider.comBTIG Reaffirms Their Hold Rating on Nuvation Bio (NUVB)May 4, 2023 | msn.comNuvation Bio GAAP EPS of -$0.10May 4, 2023 | finance.yahoo.comNuvation Bio Reports First Quarter 2023 Financial Results and Provides Business UpdateMarch 24, 2023 | markets.businessinsider.comAnalyst Expectations for Nuvation Bio's FutureMarch 24, 2023 | markets.businessinsider.comNuvation Bio (NUVB) Gets a Buy from H.C. WainwrightMarch 24, 2023 | markets.businessinsider.comWhere Nuvation Bio Stands With AnalystsMarch 20, 2023 | markets.businessinsider.comBTIG Keeps Their Hold Rating on Nuvation Bio (NUVB)March 16, 2023 | markets.businessinsider.comWedbush Sticks to Their Buy Rating for Nuvation Bio (NUVB)March 15, 2023 | finance.yahoo.comNuvation Bio Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business UpdateMarch 11, 2023 | benzinga.comNuvation Bio Stock (NYSE:NUVB), Guidance and ForecastFebruary 17, 2023 | finance.yahoo.comWith 48% stake, Nuvation Bio Inc. (NYSE:NUVB) seems to have captured institutional investors' interestFebruary 16, 2023 | nasdaq.comDeep Track Capital Now Owns 3.76% of Nuvation Bio (NUVB)January 27, 2023 | seekingalpha.comNUVB Nuvation Bio Inc.January 17, 2023 | finance.yahoo.comCompanies Like Nuvation Bio (NYSE:NUVB) Are In A Position To Invest In GrowthDecember 19, 2022 | finance.yahoo.comNuvation Bio Doses First Patient in Phase 1b Combination Study of NUV-868See More Headlines Receive NUVB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Nuvation Bio and its competitors with MarketBeat's FREE daily newsletter. Email Address NUVB Company Calendar Last Earnings8/03/2023Today9/24/2023Next Earnings (Estimated)11/02/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNYSE:NUVB CUSIPN/A CIK1811063 Webwww.nuvationbio.com Phone332-208-6102FaxN/AEmployees54Year FoundedN/APrice Target and Rating Average Stock Price Forecast$4.38 High Stock Price Forecast$6.00 Low Stock Price Forecast$2.00 Forecasted Upside/Downside+228.9%Consensus RatingModerate Buy Rating Score (0-4)2.75 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($0.41) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-104,200,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-13.97% Return on Assets-13.61% Debt Debt-to-Equity RatioN/A Current Ratio47.51 Quick Ratio47.51 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.00 per share Price / Book0.44Miscellaneous Outstanding Shares218,940,000Free Float139,927,000Market Cap$291.19 million OptionableNot Optionable Beta0.72 7 Stocks to Buy And Hold ForeverClick the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report Key ExecutivesDr. David T. Hung M.D. (Age 65)Founder, Pres, CEO & Director Comp: $944.51kMs. Jennifer A. Fox (Age 51)CFO & Sec. Comp: $834.3kDr. David C. Hanley Ph.D. (Age 53)Chief Technical Operations Officer Comp: $586.04kDr. Gary Hattersley Ph.D. (Age 56)Chief Scientific Officer Ms. Stacy Markel (Age 58)Chief People Officer Ms. Kerry A. Wentworth (Age 50)Chief Regulatory Officer Dr. David Liu M.D. (Age 53)Ph.D., Chief Medical Officer More ExecutivesKey CompetitorsNanobiotixNASDAQ:NBTXPMV PharmaceuticalsNASDAQ:PMVPMacroGenicsNASDAQ:MGNXLexicon PharmaceuticalsNASDAQ:LXRXXeris BiopharmaNASDAQ:XERSView All CompetitorsInsiders & InstitutionsGoldman Sachs Group Inc.Bought 103,356 shares on 8/15/2023Ownership: 0.229%Alliancebernstein L.P.Bought 17,020 shares on 8/15/2023Ownership: 0.090%Wells Fargo & Company MNBought 34,603 shares on 8/15/2023Ownership: 0.025%XTX Topco LtdSold 16,021 shares on 8/15/2023Ownership: 0.015%Royal Bank of CanadaBought 8,687 shares on 8/15/2023Ownership: 0.007%View All Insider TransactionsView All Institutional Transactions NUVB Stock - Frequently Asked Questions Should I buy or sell Nuvation Bio stock right now? 4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Nuvation Bio in the last year. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" NUVB shares. View NUVB analyst ratings or view top-rated stocks. What is Nuvation Bio's stock price forecast for 2023? 4 Wall Street analysts have issued twelve-month target prices for Nuvation Bio's stock. Their NUVB share price forecasts range from $2.00 to $6.00. On average, they predict the company's stock price to reach $4.38 in the next year. This suggests a possible upside of 228.9% from the stock's current price. View analysts price targets for NUVB or view top-rated stocks among Wall Street analysts. How have NUVB shares performed in 2023? Nuvation Bio's stock was trading at $1.92 at the beginning of 2023. Since then, NUVB stock has decreased by 30.7% and is now trading at $1.33. View the best growth stocks for 2023 here. When is Nuvation Bio's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, November 2nd 2023. View our NUVB earnings forecast. How were Nuvation Bio's earnings last quarter? Nuvation Bio Inc. (NYSE:NUVB) issued its quarterly earnings results on Thursday, August, 3rd. The company reported ($0.09) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.11) by $0.02. What ETF holds Nuvation Bio's stock ? Range Cancer Therapeutics ETF holds 70,984 shares of NUVB stock, representing 1.25% of its portfolio. What is Nuvation Bio's stock symbol? Nuvation Bio trades on the New York Stock Exchange (NYSE) under the ticker symbol "NUVB." Who are Nuvation Bio's major shareholders? Nuvation Bio's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include State Street Corp (1.38%), Geode Capital Management LLC (1.25%), AWM Investment Company Inc. (0.65%), Northern Trust Corp (0.57%), Prosight Management LP (0.50%) and Charles Schwab Investment Management Inc. (0.48%). Insiders that own company stock include Fund V LP Omega, Kathryn E Falberg and Oleg Nodelman. View institutional ownership trends. How do I buy shares of Nuvation Bio? Shares of NUVB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Nuvation Bio's stock price today? One share of NUVB stock can currently be purchased for approximately $1.33. How much money does Nuvation Bio make? Nuvation Bio (NYSE:NUVB) has a market capitalization of $291.19 million. The company earns $-104,200,000.00 in net income (profit) each year or ($0.41) on an earnings per share basis. How can I contact Nuvation Bio? Nuvation Bio's mailing address is 1500 BROADWAY SUITE 1401, NEW YORK NY, 10036. The official website for the company is www.nuvationbio.com. The company can be reached via phone at 332-208-6102 or via email at ir@nuvationbio.com. This page (NYSE:NUVB) was last updated on 9/24/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nuvation Bio Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.